HCPLive Network

Benefits of Early Initiation of Treatment in HIV-infected Individuals

 
During the “Reach for the Top: Can We Perfect Current ART?” abstract session held at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), researchers presented evidence showing that initiating antiretroviral therapy (ART) in chronically HIV-1 infected patients before their CD4+ count falls below 500/mm3 leads to better outcomes.
 
In their study “In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm3 achieves better HIV-1 reservoirs' depletion and T cell count restoration,” Laurent Hocqueloux, MD, and colleagues looked at a cohort of chronically infected patients patients being treated with efficient cART who had a normal CD4+ T cell count  (≥900/mm3), a normal CD4/CD8 ratio (>1), and a low HIV-DNA level (<2.3 Logcp/106 PBMC) “according to their nadir CD4+ T cell count prior to starting ART.
 
Patients were stratified according to CD4+ nadir: >500, 350-500, 200-350 and < 200 cells/mm3. They measured total HIV-DNA in PBMC at least once a year before (when possible) and during treatment. They also measured T-cell count (CD4+, CD8+) and PVL every 3-4 months.


Further Reading
A new report says a broader base of funders committed to sustained support of HIV prevention research is need to ensure continued progress in the fight to end the AIDS epidemic.
HIV-infected patients face increased risk of myocardial infarction, as well as higher risk for ART-associated dyslipidemia and insulin resistance.
A panel of experts discuss information from late-breaking abstracts presented at IAS 2013, including information on the two patients who remain HIV-free following stem cell transplant.
More Reading
$related2$
$AD300x250BB$